Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Dicker

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Leukemia|June 19, 2019
DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational patternLuca Vincenzo Cappelli, Manja Meggendorfer, Frank Dicker, et al.
Leukemia|April 29, 2023
AML classification in the year 2023: How to avoid a Babylonian confusion of languagesSandra Huber, Constance Baer, Stephan Hutter, et al.
Haematologica|April 19, 2012
Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflowSusanne Schnittger, Ulrike Bacher, Christiane Eder, et al.
Blood|June 3, 2006
CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53Frank Dicker, Arnon P Kater, Carlos E Prada, et al.
Genes, Chromosomes & Cancer|November 7, 2015
Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemiaSimone Weber, Claudia Haferlach, Sabine Jeromin, et al.
Leukemia|August 12, 2023
Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICCSandra Huber, Constance Baer, Stephan Hutter, et al.
Leukemia|August 11, 2021
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alterationLuca Vincenzo Cappelli, Manja Meggendorfer, Constance Baer, et al.
Blood|May 26, 2005
Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosisArnon P Kater, Frank Dicker, Massimo Mangiola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2010
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1Alexander Kohlmann, Vera Grossmann, Hans-Ulrich Klein, et al.
Clinical Toxicology (Philadelphia, Pa.)|August 7, 2025
Crotalidae polyvalent immune Fab (ovine) dosing in <i>Agkistrodon contortrix</i> envenomation: a single-center retrospective cohort studyKevin Baumgartner, Frank Dicker, Kim-Long Nguyen, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Leukemia|June 19, 2019
DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational patternLuca Vincenzo Cappelli, Manja Meggendorfer, Frank Dicker, et al.
Leukemia|April 29, 2023
AML classification in the year 2023: How to avoid a Babylonian confusion of languagesSandra Huber, Constance Baer, Stephan Hutter, et al.
Haematologica|April 19, 2012
Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflowSusanne Schnittger, Ulrike Bacher, Christiane Eder, et al.
Blood|June 3, 2006
CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53Frank Dicker, Arnon P Kater, Carlos E Prada, et al.
Genes, Chromosomes & Cancer|November 7, 2015
Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemiaSimone Weber, Claudia Haferlach, Sabine Jeromin, et al.
Leukemia|August 12, 2023
Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICCSandra Huber, Constance Baer, Stephan Hutter, et al.
Leukemia|August 11, 2021
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alterationLuca Vincenzo Cappelli, Manja Meggendorfer, Constance Baer, et al.
Blood|May 26, 2005
Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosisArnon P Kater, Frank Dicker, Massimo Mangiola, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2010
Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1Alexander Kohlmann, Vera Grossmann, Hans-Ulrich Klein, et al.
Clinical Toxicology (Philadelphia, Pa.)|August 7, 2025
Crotalidae polyvalent immune Fab (ovine) dosing in <i>Agkistrodon contortrix</i> envenomation: a single-center retrospective cohort studyKevin Baumgartner, Frank Dicker, Kim-Long Nguyen, et al.
Pageof 5